Rituxan is not associated with Stevens Johnson Syndrome

Annals of Oncology

Volumn 22, Issue 6, 2011, Pages 1463-1464

  Henning, J S ^a   Firoz, B F ^b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

CELL INFILTRATION; DRUG ERUPTION; DRUG FATALITY; DRUG WITHDRAWAL; EOSINOPHIL; HUMAN; IMMUNOFLUORESCENCE; LETTER; LYMPHOCYTIC INFILTRATION; NONHODGKIN LYMPHOMA; PARANEOPLASTIC PEMPHIGUS; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME;

EID: 79957825742     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr254     Document Type: Letter

References (3)

1. Lowndes S, Darby A, Mead G, Lister A. Steven's-Johnson Syndrome after treatment with rituximab. Ann Oncol 2002; 13: 1948-1950.
2. Palmieri TL, Greenhalgh DG, Shaffle JS, et al. A multicenter review of toxic epidermal necrolysis treated in US Burn Centers at the end of the twentieth century. J Burn Care Rehabil 2002; 23(2): 87-96.
3. Cummins DL, Mimouni D, Tzu J, et al. Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies. J Am Acad Dermatol 2007; 56(1): 153-159. Epub 2006 Sep 14.